Published in Scientifica (Cairo) on July 02, 2014
A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med (2005) 26.02
Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med (2013) 16.33
Predominant autoantibody production by early human B cell precursors. Science (2003) 13.14
TAK1 is a ubiquitin-dependent kinase of MKK and IKK. Nature (2001) 11.84
The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci U S A (2010) 8.05
Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med (1999) 7.41
Antigen receptor tail clue. Nature (1989) 7.32
ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med (2003) 6.82
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med (2013) 6.70
Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med (2014) 6.06
Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood (2011) 5.98
The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood (2010) 5.95
Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood (2009) 5.84
Receptor editing: an approach by autoreactive B cells to escape tolerance. J Exp Med (1993) 5.49
Clonal deletion of B lymphocytes in a transgenic mouse bearing anti-MHC class I antibody genes. Nature (1989) 5.48
Inositol phosphatase SHIP1 is a primary target of miR-155. Proc Natl Acad Sci U S A (2009) 5.30
The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood (2011) 5.06
Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression. Proc Natl Acad Sci U S A (2002) 4.86
Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med (2001) 4.83
Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity (2004) 4.42
The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. Blood (2012) 4.17
Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. J Clin Invest (1998) 3.96
The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood (2011) 3.87
PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med (2014) 3.86
B cell antigen receptor signaling 101. Mol Immunol (2004) 3.58
Cooperative inhibition of T-cell antigen receptor signaling by a complex between a kinase and a phosphatase. J Exp Med (1999) 3.48
BAFF mediates survival of peripheral immature B lymphocytes. J Exp Med (2000) 3.43
Akt signalling in health and disease. Cell Signal (2011) 3.42
Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia. Blood (2002) 3.38
B cells acquire antigen from target cells after synapse formation. Nature (2001) 3.31
Multiple defects in the immune system of Lyn-deficient mice, culminating in autoimmune disease. Cell (1995) 3.17
P110delta, a novel phosphoinositide 3-kinase in leukocytes. Proc Natl Acad Sci U S A (1997) 3.09
Characterization of the B lymphocyte populations in Lyn-deficient mice and the role of Lyn in signal initiation and down-regulation. Immunity (1997) 3.07
Identification of anergic B cells within a wild-type repertoire. Immunity (2006) 3.07
Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy. Blood (2014) 2.94
Structural basis for activation of human lymphocyte kinase Lck upon tyrosine phosphorylation. Nature (1996) 2.94
Protein kinase C: poised to signal. Am J Physiol Endocrinol Metab (2009) 2.81
ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. Lancet (2004) 2.79
Multiple distinct sets of stereotyped antigen receptors indicate a role for antigen in promoting chronic lymphocytic leukemia. J Exp Med (2004) 2.79
Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: Pathogenetic implications and clinical correlations. Blood (2006) 2.77
Chronic lymphocytic leukemia: revelations from the B-cell receptor. Blood (2004) 2.71
Constitutive activation of distinct BCR-signaling pathways in a subset of CLL patients: a molecular signature of anergy. Blood (2008) 2.71
The kinetic-segregation model: TCR triggering and beyond. Nat Immunol (2006) 2.70
Essential, nonredundant role for the phosphoinositide 3-kinase p110delta in signaling by the B-cell receptor complex. Mol Cell Biol (2002) 2.70
The MAGUK family protein CARD11 is essential for lymphocyte activation. Immunity (2003) 2.67
BLNK: a central linker protein in B cell activation. Immunity (1998) 2.59
Chronic lymphocytic leukaemia. Lancet (2008) 2.59
Cloning and characterization of a lymphoid-specific, inducible human protein tyrosine phosphatase, Lyp. Blood (1999) 2.40
Unmutated and mutated chronic lymphocytic leukemias derive from self-reactive B cell precursors despite expressing different antibody reactivity. J Clin Invest (2005) 2.40
Association of inhibitory tyrosine protein kinase p50csk with protein tyrosine phosphatase PEP in T cells and other hemopoietic cells. EMBO J (1996) 2.37
Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling. Nature (2012) 2.36
Different nuclear signals are activated by the B cell receptor during positive versus negative signaling. Immunity (1997) 2.34
ZAP-70 directly enhances IgM signaling in chronic lymphocytic leukemia. Blood (2004) 2.30
The CARMA1 signalosome links the signalling machinery of adaptive and innate immunity in lymphocytes. Nat Rev Immunol (2006) 2.25
HS1 functions as an essential actin-regulatory adaptor protein at the immune synapse. Immunity (2006) 2.23
Production of autoantibodies by CD5-expressing B lymphocytes from patients with chronic lymphocytic leukemia. J Exp Med (1989) 2.16
Reduced life span of anergic self-reactive B cells in a double-transgenic model. J Exp Med (1994) 2.15
B-cell receptor signaling in chronic lymphocytic leukemia. Blood (2011) 2.11
Unusual interplay of two types of Ras activators, RasGRP and SOS, establishes sensitive and robust Ras activation in lymphocytes. Mol Cell Biol (2007) 2.05
Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia. Blood (2010) 2.04
Essential role of Src-family protein tyrosine kinases in NF-kappaB activation during B cell development. Nat Immunol (2003) 2.04
Clonal anergy: persistence in tolerant mice of antigen-binding B lymphocytes incapable of responding to antigen or mitogen. Proc Natl Acad Sci U S A (1980) 2.04
Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL). Blood (2013) 2.03
ZAP-70 enhances IgM signaling independent of its kinase activity in chronic lymphocytic leukemia. Blood (2007) 2.00
ZAP-70 enhances B-cell-receptor signaling despite absent or inefficient tyrosine kinase activation in chronic lymphocytic leukemia and lymphoma B cells. Blood (2006) 1.95
Remarkably similar antigen receptors among a subset of patients with chronic lymphocytic leukemia. J Clin Invest (2004) 1.94
BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity. Leukemia (2013) 1.94
ZAP-70 methylation status is associated with ZAP-70 expression status in chronic lymphocytic leukemia. Haematologica (2005) 1.93
Chronic lymphocytic leukemia B cells contain anomalous Lyn tyrosine kinase, a putative contribution to defective apoptosis. J Clin Invest (2005) 1.93
Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B cells. Leukemia (2008) 1.92
Bruton's tyrosine kinase and phospholipase Cgamma2 mediate chemokine-controlled B cell migration and homing. Immunity (2007) 1.92
ZAP-70 expression is associated with enhanced ability to respond to migratory and survival signals in B-cell chronic lymphocytic leukemia (B-CLL). Blood (2005) 1.91
Sustained signaling through the B-cell receptor induces Mcl-1 and promotes survival of chronic lymphocytic leukemia B cells. Blood (2005) 1.88
BCAP: the tyrosine kinase substrate that connects B cell receptor to phosphoinositide 3-kinase activation. Immunity (2000) 1.86
Differential signaling via surface IgM is associated with VH gene mutational status and CD38 expression in chronic lymphocytic leukemia. Blood (2002) 1.85
Autocrine VEGF mediates the antiapoptotic effect of CD154 on CLL cells. Leukemia (2005) 1.80
Syk protein-tyrosine kinase is regulated by tyrosine-phosphorylated Ig alpha/Ig beta immunoreceptor tyrosine activation motif binding and autophosphorylation. J Biol Chem (1995) 1.78
Phosphoinositide 3-kinase p110 delta regulates natural antibody production, marginal zone and B-1 B cell function, and autoantibody responses. J Immunol (2009) 1.77
RasGRP1 and RasGRP3 regulate B cell proliferation by facilitating B cell receptor-Ras signaling. J Immunol (2005) 1.70
Targeting B-cell anergy in chronic lymphocytic leukemia. Blood (2013) 1.66
Spleen tyrosine kinase is overexpressed and represents a potential therapeutic target in chronic lymphocytic leukemia. Cancer Res (2009) 1.65
Phospholipase C-gamma2 and Vav cooperate within signaling microclusters to propagate B cell spreading in response to membrane-bound antigen. J Exp Med (2008) 1.63
Role of the Syk autophosphorylation site and SH2 domains in B cell antigen receptor signaling. J Exp Med (1995) 1.62
Ig VH1 genes expressed in B cell chronic lymphocytic leukemia exhibit distinctive molecular features. J Immunol (1997) 1.61
Overexpression of the autoimmunity-associated phosphatase PTPN22 promotes survival of antigen-stimulated CLL cells by selectively activating AKT. Blood (2012) 1.61
A novel spleen tyrosine kinase inhibitor blocks c-Jun N-terminal kinase-mediated gene expression in synoviocytes. J Pharmacol Exp Ther (2006) 1.60
The differential expression of LCK and BAFF-receptor and their role in apoptosis in human lymphomas. Haematologica (2006) 1.60
Evidence that chronic lymphocytic leukemia B lymphocytes are frequently committed to production of natural autoantibodies. Blood (1990) 1.58
PKC beta regulates BCR-mediated IKK activation by facilitating the interaction between TAK1 and CARMA1. J Exp Med (2005) 1.57
Nonreceptor protein-tyrosine phosphatases in immune cell signaling. Annu Rev Immunol (2007) 1.56
Quantitative DNA methylation analysis identifies a single CpG dinucleotide important for ZAP-70 expression and predictive of prognosis in chronic lymphocytic leukemia. J Clin Oncol (2012) 1.56
B cell receptors in TCL1 transgenic mice resemble those of aggressive, treatment-resistant human chronic lymphocytic leukemia. Proc Natl Acad Sci U S A (2006) 1.55
Reversible anergy of sIgM-mediated signaling in the two subsets of CLL defined by VH-gene mutational status. Blood (2007) 1.55
Structurally distinct phosphatases CD45 and CD148 both regulate B cell and macrophage immunoreceptor signaling. Immunity (2008) 1.54
Vascular endothelial growth factor stimulates protein kinase CbetaII expression in chronic lymphocytic leukemia cells. Blood (2010) 1.51
Protein tyrosine phosphatases in lymphocyte activation and autoimmunity. Nat Immunol (2012) 1.50
Identification of HS1 protein as a major substrate of protein-tyrosine kinase(s) upon B-cell antigen receptor-mediated signaling. Proc Natl Acad Sci U S A (1993) 1.49